Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer

Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer

While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced

(Visited 4 times, 1 visits today)
3
Like
Save

Comments

Write a comment